Genpact LTD (G) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Genpact LTD’s revenue went from $2.6B in fiscal 2016 to $5.1B in fiscal 2025, growth of about 7.9% a year.
Net income in fiscal 2025 was $552M, a net margin of 10.9%; the best year in this period was 2023 with $631M.
Over the twelve months to September 30, 2026, revenue was $5.3B and net income $588M.
Free cash flow was $735M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 16% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.3B | $5.1B | $4.8B | $4.5B | $4.4B | $4.0B | $3.7B | $3.5B | $3.0B | $2.7B | $2.6B |
| Gross profit | $2.0B | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $1.0B |
| Operating income | $798M | $750M | $702M | $631M | $502M | $509M | $439M | $429M | $348M | $331M | $341M |
| Net income | $588M | $552M | $514M | $631M | $353M | $369M | $308M | $305M | $282M | $263M | $270M |
| EPS (diluted) | $3.43 | $3.13 | $2.85 | $3.41 | $1.88 | $1.91 | $1.57 | $1.56 | $1.45 | $1.34 | $1.28 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +6.6% | +6.5% | +2.4% | +8.7% | +8.4% | +5.4% | +17.3% | +9.6% | +6.5% | +4.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $429M | $813M | $615M | $491M | $444M | $694M | $584M | $428M | $340M | $359M | $346M |
| Capital spending | -$72M | -$78M | -$83M | -$55M | -$51M | -$53M | -$70M | -$75M | -$85M | -$57M | -$82M |
| Free cash flow | $357M | $735M | $533M | $435M | $393M | $641M | $514M | $353M | $255M | $302M | $264M |
| Dividends paid | $124M | $118M | $108M | $100M | $92M | $80M | $74M | $65M | $57M | $47M | — |
| Buybacks | — | — | $253M | $225M | $214M | $298M | $137M | $30M | $154M | $220M | $345M |
| Stock-based pay | $105M | $90M | $66M | $89M | $77M | $82M | $74M | $84M | $49M | $36M | $25M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.2B | $672M | $584M | $647M | $899M | $680M | $467M | $368M | $504M | $423M |
| Debt | — | $1.7B | $1.4B | $1.5B | $1.5B | $2.0B | $1.7B | $1.7B | $1.0B | $1.0B | $737M |
| Equity | — | $2.5B | $2.4B | $2.2B | $1.8B | $1.9B | $1.8B | $1.7B | $1.4B | $1.4B | $1.3B |
| Total assets | — | $5.8B | $5.0B | $4.8B | $4.6B | $5.0B | $4.9B | $4.5B | $3.5B | $3.4B | $2.9B |
| Shares (diluted) | 170M | 177M | 180M | 185M | 188M | 193M | 196M | 195M | 194M | 197M | 210M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 36.9% | 36.0% | 35.4% | 35.1% | 35.1% | 35.6% | 34.8% | 34.8% | 36.0% | 38.6% | 39.5% |
| Operating margin | 14.9% | 14.8% | 14.7% | 14.1% | 11.5% | 12.7% | 11.8% | 12.2% | 11.6% | 12.1% | 13.3% |
| Net margin | 11.0% | 10.9% | 10.8% | 14.1% | 8.1% | 9.2% | 8.3% | 8.7% | 9.4% | 9.6% | 10.5% |
| FCF margin | 6.7% | 14.5% | 11.2% | 9.7% | 9.0% | 15.9% | 13.9% | 10.0% | 8.5% | 11.0% | 10.3% |
| ROIC | — | 13.2% | 14.0% | 13.4% | 11.4% | 10.1% | 9.6% | 9.6% | 11.2% | 10.9% | 13.7% |
| ROE | — | 21.7% | 21.5% | 28.1% | 19.4% | 19.5% | 16.8% | 18.1% | 20.1% | 18.5% | 21.0% |
Frequently asked questions
What is Genpact LTD’s annual revenue?
$5.1B in fiscal 2025 and $5.3B over the twelve months to September 30, 2026.
How much profit does Genpact LTD make?
Net income was $552M in fiscal 2025 (net margin 10.9%).
Is Genpact LTD’s revenue growing?
Yes: revenue rose 6.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.